Ivy Tree Advisors reported that Boehringer Ingelheim moved at a pace that shows it in 2026 AI activity, including signing four significant AI discovery partnerships in 2026 and investing £150 million over ten years to open a new AI accelerator in London’s Knowledge Quarter.
Published
Signal category
Customers & Market
Quote
“Boehringer Ingelheim doesn’t have to answer quarterly earnings calls, and its 2026 AI activity has moved at a pace that shows it.”
— Jonathan Olsen, MBA|Ivy Tree Advisors team
Company
Ivy Tree Advisors
Management and Strategy Consulting for HealthTech and Biopharma
- Industry
- Pharmaceutical Manufacturing
- Location
- Boston, US
- Company size
- 4 employees
Ivy Tree Advisors is a network consultancy of 30+ consultants from the world's top companies and successful health ventures who possess deep expertise and a successful track record. We routinely perform and execute market entry strategy, commercialization, and product launch for both health tech ventures and large established organizations seeking to innovate and grow. We help drive traction for innovative products in pharmaceuticals, health tech, and technology. Exceptional results come from smart product planning and execution tailored to your market.
Founded 2016